Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Human CD32b/c Protein, Strep Tag (Cat. No. CDB-H5284) immobilized on CM5 Chip can bind Rituximab with an affinity constant of 10.2 μM as determined in a SPR assay (Biacore 8K) (QC tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic | Details |
PRV-3279 | HDM-3002; MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Lupus Erythematosus, Systemic | Details |
BI-1206 | 6G-11; BI-1206 | Phase 2 Clinical | Bioinvent International Ab | Lymphoma, B-Cell; Solid tumours; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
BI-1607 | BI-1607 | Phase 2 Clinical | Bioinvent International Ab | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Metastatic breast cancer; Adenocarcinoma | Details |
NVG-2089 | NVG-2089 | Phase 1 Clinical | Nuvig Therapeutics Inc | Details | |
Obexelimab | XmAb-5871; AMG-729 | Phase 3 Clinical | Xencor Inc | Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic | Details |
PRV-3279 | HDM-3002; MGD-010; PRV-3279; CD32BxCD79B | Phase 2 Clinical | Macrogenics Inc | Lupus Erythematosus, Systemic | Details |
BI-1206 | 6G-11; BI-1206 | Phase 2 Clinical | Bioinvent International Ab | Lymphoma, B-Cell; Solid tumours; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
BI-1607 | BI-1607 | Phase 2 Clinical | Bioinvent International Ab | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Breast Neoplasms; Metastatic breast cancer; Adenocarcinoma | Details |
NVG-2089 | NVG-2089 | Phase 1 Clinical | Nuvig Therapeutics Inc | Details |
This web search service is supported by Google Inc.